Forging a path for MedTech Innovation.
Erectile dysfunction (ED) is a global health concern, projected to affect over 322 million men in 2025. For many, oral medications offer relief. However, for a growing subset—post-prostatectomy patients, individuals with diabetes or cardiovascular disease, and those undergoing gender-affirming procedures—implantable penile prostheses (IPPs) offer a long-term, highly effective solution. Despite their clinical effectiveness and high patient satisfaction rates, access to and awareness of penile prostheses remains limited in many parts of the world.
The U.S. once accounted for 85.9% of all penile prosthesis surgeries. Today, its share is estimated at 70–80%, reflecting a growing adoption in markets such as Germany, Australia, and Japan.
Satisfaction rates for IPPs consistently exceed 90% in clinical studies. Still, penile implants are often perceived as a “last resort,” rather than a mainstream solution. This perception contributes to underutilization, especially in markets where awareness and training are limited.
Many international markets still lag in the adoption of penile prostheses due to:
For example, while the U.S. performs over 25,000 penile implant procedures annually, Germany performs approximately 1,200.
The gap highlights significant room for growth—particularly in regions with aging populations, rising ED prevalence, and maturing healthcare infrastructure.
Recent innovations have improved patient outcomes and broadened clinical options:
These developments are making the procedure more attractive to both surgeons and patients.
MedTech companies operating in this space face a two-fold opportunity:
As the demand for sexual health solutions rises, combining clinical innovation with strategic market entry will be key to unlocking new value.
Penile prostheses are entering a new era. Once relegated to niche procedures, they are now part of a broader, global conversation about men’s health, quality of life, and sexual well-being.
For MedTech innovators, this market represents not only clinical impact but significant growth potential—especially for those willing to invest in education, accessibility, and innovation on a global scale.
These insights are powered by IQVIA’s MedTech Market Monitor (MMM), a global platform offering real-world data on surgical procedures across 45 countries.
As global healthcare systems continue to evolve, real-time access to surgical procedure data is becoming key to understanding healthcare market dynamics. This solution provides exceptional visibility into high-impact therapeutic areas, enabling manufacturers, investors, and clinical leaders to track global trends, benchmark market penetration, anticipate emerging opportunities, and more.
Click the CONTACT US button to make an enquiry.
Forging a path for MedTech Innovation.
Connected commercial solutions, maximizing market performance.